Composition Comprising Thrombin-Treated Stem Cell-Derived Exosome For Treating Skin Wound

Abstract

The present disclosure relates to a pharmaceutical composition comprising an exosome derived from a thrombin-treated stem cell as an effective ingredient for preventing or treating a skin wound, a pharmaceutical formulation containing the same, and a production method thereof. Being a cell-free agent, an exosome-based therapeutic agent of the present disclosure has a low risk of carcinogenesis and no problems of graft rejection as well as being little liable to occur microvascular obstruction. The agent, which is not a cell, but a material isolated from a cell, can be subjected to medication development into an off-the-shelf product which allows for the reduction of production cost. The agent has the advantage of exhibiting outstanding angiogenesis and skin wound treatment effects even at a low concentration of exosomes thanks to the thrombin treatment effect.

Dependencies are inferred from the claim text.